STOCKHOLM, SWEDEN — June 21, 2002 —
Postmenopausal women overwhelmingly prefer a once weekly dosing regimen of Fosamax® (alendronate) over a once daily routine.
The results of this study were presented here this week at the Annual European Congress of Rheumatology (EULAR). Dr. L. Kendler from the department of endocrinology at St. Vincent’s Hospital in Vancouver, British Columbia, Canada, led a team of researchers who recruited 405 postmenopausal women from 45 study sites in Europe, the Americas, and the Asian Pacific Region.
These patients were randomly assigned to treatment with alendronate 70 mg once weekly followed by alendronate 10 mg daily or alendronate 10 mg daily followed by alendronate 70 mg once weekly in an open-label design. Each treatment was given for four weeks using standard AM dosing.
After patients had experienced both treatment regimens, they completed a questionnaire assessing their preference and willingness to take the regimens long-term. Overall, 92 percent of patients preferred a specific dosing regimen, and 84 percent of these patients said they preferred the once weekly regimen. 87 percent of patients reported that the weekly regimen is more convenient, and 84 percent indicated that they would pick the weekly regimen as the one they would prefer to take over the long term.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!